Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.979,48
-0,15%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Soligenix Inc (SNGX) Soligenix Inc (SNGX) Notizie

SNGX

Soligenix (SNGX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SNGX
DataOraFonteTitoloSimboloCompagnia
17/05/202422:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNGXSoligenix Inc
17/05/202422:09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SNGXSoligenix Inc
16/05/202413:30PR Newswire (US)Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical PracticeNASDAQ:SNGXSoligenix Inc
10/05/202422:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SNGXSoligenix Inc
10/05/202422:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNGXSoligenix Inc
10/05/202413:30PR Newswire (US)Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial ResultsNASDAQ:SNGXSoligenix Inc
06/05/202413:30PR Newswire (US)Soligenix to Present at Upcoming ConferencesNASDAQ:SNGXSoligenix Inc
25/04/202413:30PR Newswire (US)Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South AfricaNASDAQ:SNGXSoligenix Inc
18/04/202414:30PR Newswire (US)Soligenix Announces Pricing of $4.75 Million Public OfferingNASDAQ:SNGXSoligenix Inc
15/04/202413:30PR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus InfectionNASDAQ:SNGXSoligenix Inc
11/04/202413:30PR Newswire (US)FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus InfectionNASDAQ:SNGXSoligenix Inc
03/04/202413:30PR Newswire (US)Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines AgencyNASDAQ:SNGXSoligenix Inc
15/03/202412:30PR Newswire (US)Soligenix Announces Recent Accomplishments and Year End 2023 Financial ResultsNASDAQ:SNGXSoligenix Inc
08/02/202413:30PR Newswire (US)Soligenix Announces Formation of Behçet's Disease Medical Advisory BoardNASDAQ:SNGXSoligenix Inc
25/01/202413:30PR Newswire (US)Soligenix to Present at The Microcap ConferenceNASDAQ:SNGXSoligenix Inc
08/01/202413:30PR Newswire (US)FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
04/01/202413:30PR Newswire (US)Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate PsoriasisNASDAQ:SNGXSoligenix Inc
02/01/202413:30PR Newswire (US)Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg VirusesNASDAQ:SNGXSoligenix Inc
18/12/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SNGXSoligenix Inc
15/12/202322:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SNGXSoligenix Inc
08/12/202322:05Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SNGXSoligenix Inc
01/12/202313:30PR Newswire (US)"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug DiscoveryNASDAQ:SNGXSoligenix Inc
30/11/202313:30PR Newswire (US)Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's DiseaseNASDAQ:SNGXSoligenix Inc
17/11/202322:00PR Newswire (US)Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual MeetingNASDAQ:SNGXSoligenix Inc
13/11/202313:30PR Newswire (US)Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial ResultsNASDAQ:SNGXSoligenix Inc
16/10/202313:30PR Newswire (US)Soligenix to Present at The ThinkEquity ConferenceNASDAQ:SNGXSoligenix Inc
25/09/202313:30PR Newswire (US)Soligenix Announces Achievement of Two-Year Stability with Bivalent and Trivalent Thermostabilized Filovirus Vaccines when Stored at High TemperaturesNASDAQ:SNGXSoligenix Inc
22/09/202322:00PR Newswire (US)Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting and Additional Proposal to be Considered by StockholdersNASDAQ:SNGXSoligenix Inc
30/08/202322:05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SNGXSoligenix Inc
21/08/202313:30PR Newswire (US)Soligenix Announces Recent Accomplishments And Second Quarter 2023 Financial ResultsNASDAQ:SNGXSoligenix Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SNGX

La tua Cronologia

NASDAQ
WAVD
WaveDancer
EU
D154T
D154T
COIN
SHFTGBP
Shyft [ Wrapped ]
BIT
F19206
Vontobel Financial Produ...
BOV
DGCO34Q
Dollar General
USOTC
FTGAF
Freetrailer Group AS (GM)
EU
E062T
E062T
BMF
DOLH17
ASX
LSH
Lifespot Health
ASE
ARBA
ASX
FMGJOG
USOTC
NOEC
New Oriental Energy and ... (CE)
TG
BNN
BRAIN Biotech
NASDAQ
BSGM
BioSig Technologies
COIN
MDUSUST
Medieus Token
AMEX
XTNT
Xtant Medical
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network